E. A. Ulyanova

E. A. Ulyanova

Auto-generated profile, based on publicly available information

E. A. Ulyanova

Russian University of Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2025 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
DVD. A. Vyzhigin
D. A. Vyzhigin
ESE. Y. Shupenina
E. Y. Shupenina
ENE. O. Novosel
E. O. Novosel
EUE. A. Ulyanova
E. A. Ulyanova
Aim. To study new possibilities of the potential of speckle tracking echocardiography for detecting early subclinical cardiotoxicity of chemo- and targeted therapy.Material and methods. 150 patients with a verified oncological diagnosis, with a very high or high risk of cardiotoxicity, determined by the Mayo Clinic scale, were included in the prospective observational study at the Department of Hospital Therapy No. 1 of the Russian Medical University of the Ministry of Health of Russia in 2021-2023. All enrolled patients were recommended to take a fixed combination of the ACE inhibitor perindopril and the beta-blocker bisoprolol (5+5 mg) 5-7 days before the start of chemo-targeted therapy. Patients with a very high risk of cardiotoxicity who were diagnosed with ischemic chronic heart failure or stable coronary artery disease, or post-myocardial infarction, were additionally recommended to take long-acting trimetazidine OD at a dose of 80 mg once daily. At the second visit, the main group (n=84, receiving cardioprotective drugs) and the comparison group (n=66, not receiving cardioprotective drugs) were formed. All patients at the time of inclusion in the study, as well as 1, 3, 6, 9 and 12 months after the start of antitumor therapy, underwent the following assessment: collecting complaints, anamnesis data, physical examination, ECG registration in 12 standard leads, and a two-dimensional echocardiogram with the measurement of left ventricular (LV) global longitudinal strain (GLS).Results. Primary drug prophylaxis in cancer patients with high and very high risk of cardiotoxicity was associated with a 2.7-fold decrease in significant cardiovascular complications. The development of chronic heart failure in the main group was noted 7 times less frequently than in the comparison group (n=1 (1.2%) vs n=7 (10.6%), p<0.05), a decrease in GLS LV 2.6 times (n=5 (5.9%) vs n=13 (19.7%), p-18%, compensatory hyperkinesia of LV apical segments contractility <-18% in the inner part of the diagram compared to the initially determined values of the LV longitudinal strain before the start of antitumor therapy is an early, preclinical sign of cardiotoxicity.Conclusion. The detection of typical changes in local longitudinal strain should be considered as an early sign of cardiotoxicity with a subsequent change in treatment tactics: temporary or permanent withdrawal of the drugs that caused cardiovascular complications, the appointment of cardioprotective therapy with ACE inhibitors, beta-adrenergic blockers and myocardial cytoprotectors.

15 August 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AGA. N. Golosova
A. N. Golosova
SGS. V. Gatsura
S. V. Gatsura
EUE. A. Ulyanova
E. A. Ulyanova
ZDZh. Yu. Dvoryanchikova
Zh. Yu. Dvoryanchikova
Особенности выбора двойной антитромбоцитарной терапии у больных острым коронарным синдромом после чрескожного коронарного вмешательства

9 September 2026 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
AGA.N. Golosova
A.N. Golosova
SGS.V. Gatsura
S.V. Gatsura
ESE.IU. Shupenina
E.IU. Shupenina
EUE.A. Ulianova
E.A. Ulianova
SSS.IU. Sitnik
S.IU. Sitnik
OPO.IU. Proklova
O.IU. Proklova
Hypertrophic cardiomyopathy (HCM) in asymptomatic patients is often identified on resting electrocardiography (ECG), with diagnosis confirmed by echocardiography (EchoCG) and magnetic resonance imaging (MRI). Objective. To present a clinical case of an asymptomatic, non-obstructive form of hypertrophic cardiomyopathy characterized by the predominant localization of left ventricular hypertrophy affecting the basal anteroseptal and anterior segments of the left ventricle. A clinical case description. We report a case involving a 32-year-old asymptomatic patient, S., who was monitored after changes in the resting ECG were detected during a routine medical examination. The patient underwent Holter ECG monitoring, echocardiography with the Valsalva maneuver, bicycle ergometry, and measurement of N-terminal brain natriuretic propeptide (NT-proBNP) levels as part of an outpatient assessment. Contrast-enhanced cardiac MRI was subsequently performed at the A.N. Bakulev National Medical Research Center of Cardiovascular Surgery. ECG and echocardiographic evaluations in the patient’s parents did not reveal left ventricular (LV) anomalies or hypertrophy (LVH). Genetic testing was recommended for the patient and their relatives to identify potential mutations in genes encoding sarcomeric proteins. The findings underscore that in young, asymptomatic patients with significant alterations in the ventricular complex on the resting ECG, attention must be directed to voltage criteria for LVH, using multiple ECG parameters to achieve an accurate diagnosis. Recognition of ECG signs consistent with HCM facilitates a targeted assessment of cardiac chamber structure to detect echocardiographic markers of HCM. The use of contrast-enhanced cardiac MRI is advisable to clarify echocardiographic results, evaluate the extent of myocardial fibrosis, and rule out phenocopies of HCM. Moreover, the need for genetic testing of the patient and relatives for genes with a well-established causal association with HCM is underscored. Annual follow-up for asymptomatic patients, including an evaluation of sudden cardiac death risk, is deemed essential. Conclusions. The presented case illustrates the feasibility of detecting hypertrophic cardiomyopathy in asymptomatic young patients within an outpatient setting. An annual, comprehensive diagnostic evaluation is critical for identifying both early signs of heart failure and the progression of left ventricular outflow tract obstruction.